Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1600 1618 1674 1675
This examiner grants 0% of resolved cases
Tirone Derek Johnson is assigned to Art Unit 1600 in Tech Center 1600. The data shows 1 resolved case, which resulted in an allowance rate of 0.0 percent. This limited sample size may not fully reflect the examiner's long-term trends or typical behavior. Practitioners should view these initial results as a single data point for understanding the examiner's approach in this specific art unit.
The interview lift is also 0.0 percent. This matches the allowance rate, as the single resolved case did not result in a grant. In this specific instance, an interview did not lead to an allowance. However, with only 1 resolved case on record, it is premature to conclude that interviews are ineffective. Applicants may still find value in direct communication to explore the examiner's specific technical concerns.
The median days to allowance is 1189. This duration is based on the limited data available and provides a single reference point for pendency. To navigate a process that may last 1189 days, practitioners should focus on building a robust record. While the 0.0 percent allowance rate is based on minimal data, it underscores the importance of a thorough and well-supported application from the outset.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18588224 | COMPOSITIONS COMPRISING A BISPECIFIC GPRC5D/CD3 ANTIBODY | Non-Final OA | Janssen Biotech Inc. |
| 18029609 | PROTEIN DOUBLE-SHELL NANOSTRUCTURES AND THEIR USE | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 18278707 | MICROBIAL PRODUCTION OF POLYMERIC AMYLOID FIBERS | Non-Final OA | Washington University |
| 18331475 | CANINE CANCER VACCINE | Non-Final OA | Arizona Board of Regents on behalf of Arizona State University |
| 18163698 | ANTI-TFR:GAA AND ANTI-CD63:GAA INSERTION FOR TREATMENT OF POMPE DISEASE | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18182413 | NUCLEIC ACID ENCODING HUMAN HGF AND USE THEREOF | Non-Final OA | Peking University |
| 18276871 | METHODS OF TREATING HYPOGONADOTROPIC HYPOGONADISM AND COGNITION IMPAIRMENT FOLLOWING A TRAUMATIC BRAIN INJURY | Final Rejection | UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS |
| 18573750 | MEDICAMENT FOR TREATMENT AND/OR PREVENTION OF CANCER | Non-Final OA | TORAY INDUSTRIES, INC. |
| 18649688 | CRY PROTEIN CRYSTALS AND METHODS OF USE | Non-Final OA | Battelle Memorial Institute |
| 17913509 | TNFAIP3 AS A BIOMARKER FOR AUTOIMMUNE DISEASES | Non-Final OA | The Brigham and Women's Hospital, Inc. |
| 18258588 | INTERLEUKIN 5 BINDING PROTEIN DOSAGE REGIMEN | Non-Final OA | GlaxoSmithKline Intellectual Property Development Limited |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy